“March-in” rights provision of Bayh-Dole Act becoming an issue in drug price control debate

A new study from the Information Technology & Innovation Foundation, “The Bayh-Dole Act’s Vital Importance to the U.S. Life-Sciences Innovation System,” is caught-up in the debate over drug price controls. Specifically, the issue is over something called “march-in rights.” According to the author of this article in IPWatchdog, some are arguing that the law authorizes the government to license competitors if a resulting product isn’t “reasonably priced.”

Stay connected with us on Twitter and LinkedIn. Article ideas and other suggestions should be sent to Include the name and contact information (phone and email) for follow-up.